Home/Insights/Top Market Research Companies in the UK
    2026 Industry Guide

    Top Market Research Companies in the UK (2026 Guide)

    This guide covers market research companies operating in the UK for 2026. It profiles seven firms across healthcare, pharmaceutical, and consumer research, comparing capabilities, methodologies, and UK-specific expertise for buyers choosing a research partner.

    Published June 2026 · By BioNixus Research Team · 14 min read

    ~£30B+

    pharma market

    NHS single payer

    MHRA + NICE

    7

    firms profiled

    What are the top market research companies in the United Kingdom?

    BioNixus is a market research company that runs custom primary research in the United Kingdom from its Europe office in London.

    • Pharmaceutical Market ResearchMHRA/NICE-aligned HCP surveys, KOL mapping, formulary research, and market access studies across oncology, immunology, cardiovascular, and rare disease therapy areas.
    • Healthcare and MedTech ResearchPrimary research for NHS trusts, Integrated Care Boards (ICBs), and primary care networks across England, Scotland, and Wales.
    • Payer and Health Economics ResearchNICE technology appraisals, SMC and AWMSG submissions, VPAG pricing intelligence, and cost-effectiveness and QALY-based willingness-to-pay studies.

    UK studies cover England, Scotland, and Wales, including separate SMC and AWMSG access decisions.

    Top Market Research Companies in the UK (2026)

    The following firms have demonstrated market research capability in the UK as of 2026:

    1. 1BioNixus — HQ: Europe office: London (UK) · Americas office and global HQ: Sheridan, Wyoming (USA)
    2. 2IQVIA UK — HQ: London, UK
    3. 3Research Partnership — HQ: London, UK
    4. 4Adelphi Research — HQ: Bollington, Cheshire, UK
    5. 5Ipsos UK — HQ: London, UK
    6. 6Lumanity — HQ: UK (multiple sites) · Global
    7. 7Mtech Access — HQ: Bicester, Oxfordshire, UK

    In this guide

    UK pharmaceutical market landscape UK payer environment and NICE 7 firm profiles How to evaluate a UK research partner KOL mapping and payer research in the UK Frequently asked questions

    UK Pharmaceutical Market Landscape in 2026

    The UK is a strategically important pharmaceutical market, estimated at well over £30 billion in 2026 and representing a critical reference market for global pharmaceutical launches. The UK's publicly funded NHS means commercial success depends on navigating MHRA regulatory approval, NICE health technology appraisal (with the SMC and AWMSG covering Scotland and Wales), VPAG pricing arrangements, and local funding and adoption through Integrated Care Boards (ICBs) — all in parallel.

    UK pharmaceutical market research in 2026 is shaped by three defining dynamics:

    • NICE and devolved HTA convergence: NICE's technology appraisal process is the gatekeeper to NHS funding in England, with the SMC in Scotland and the AWMSG in Wales running parallel processes. Market researchers must design evidence aligned to NICE reference-case cost-effectiveness methodology and HTA committee decision criteria — not simply FDA or EMA standards.
    • VPAG pricing constraints: The 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) governs branded medicine spend and applies rebate (clawback) rates on sales above agreed growth. This makes net-price intelligence and willingness-to-pay research a critical component of UK market access strategy.
    • Local commissioning complexity: National HTA approval is necessary but not sufficient — Integrated Care Boards (ICBs) drive local formulary adoption, medicines optimisation, and uptake across NHS trusts and primary care networks. UK market access research must segment between national HTA stakeholders and local ICB decision-makers, with awareness of distinct NHS structures across the devolved nations.

    UK Payer Environment and NICE: What Market Researchers Must Know

    NICE, SMC and AWMSG

    NICE conducts technology appraisals that determine NHS funding in England, while the SMC (Scotland) and AWMSG (Wales) run parallel HTA processes. Market access research must align evidence to NICE reference-case methodology and devolved committee criteria.

    NHS and ICBs

    The NHS is the dominant single payer, with Integrated Care Boards (ICBs) responsible for local funding, medicines optimisation, and formulary adoption. Each ICB has distinct priorities and budget pressures that require dedicated payer research alongside national HTA work.

    VPAG and the ABPI

    VPAG constrains branded medicine spend through clawback rates on sales above agreed growth, while the ABPI Code of Practice governs industry interactions with HCPs. Payer research must account for net-price impact, affordability, and compliant HCP engagement.

    How to Evaluate a Market Research Partner for the UK

    Selecting the right UK market research partner requires criteria beyond standard RFP evaluation. The UK's NICE evidence requirements, devolved HTA processes (SMC and AWMSG), VPAG pricing constraints, UK GDPR and ABPI compliance standards, and ICB-level commissioning demand specific capabilities.

    UK GDPR and ABPI compliance

    Capability to design and execute HCP and patient research under UK GDPR / Data Protection Act 2018 and the ABPI Code of Practice, with appropriate consent, honoraria, and adverse-event handling.

    UK AMC and NHS trust HCP network (UCLH, Guy's and St Thomas', Royal Marsden, Addenbrooke's)

    Verified access to physicians and KOLs at major UK academic medical centres, cancer centres, and NHS trusts across England, Scotland, and Wales.

    NICE, SMC and AWMSG payer research

    Ability to conduct in-depth interviews aligned to NICE technology appraisal, SMC, and AWMSG processes, and with ICB medicines optimisation and formulary decision-makers.

    NICE evidence alignment

    Understanding of NICE reference-case HTA methodology, QALY thresholds, and ability to design primary research evidence aligned to cost-effectiveness and reimbursement requirements.

    HEOR and cost-effectiveness evidence generation

    Capability to generate primary willingness-to-pay data, budget impact inputs, and HEOR evidence aligned to NICE, SMC, and AWMSG review standards.

    Multi-nation (England, Scotland, Wales) fieldwork capability

    Ability to conduct research across the devolved UK nations with awareness of distinct HTA bodies and NHS structures — essential for UK-wide market access studies.

    7 Top Market Research Companies in the UK (2026)

    The following profiles cover firms with demonstrated market research capability in the UK. Each is assessed by use case and market positioning.

    1

    BioNixus

    Est. 2012HQ: Europe office: London (UK) · Americas office and global HQ: Sheridan, Wyoming (USA)

    BioNixus is a specialist pharmaceutical and healthcare market research company serving UK-based pharmaceutical, biotech, and medtech clients with MHRA- and NICE-aligned primary research. Known for deep payer intelligence across NICE technology appraisals, the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG), and verified HCP recruitment at leading UK academic medical centres and NHS trusts including UCLH, Guy's and St Thomas', The Royal Marsden, Addenbrooke's, and Manchester Royal Infirmary.

    Best for

    • MHRA- and NICE-aligned HCP surveys and KOL mapping
    • NICE, SMC and AWMSG payer and HTA submission research
    • GDPR-compliant market access evidence generation
    2

    IQVIA UK

    Est. 1982 (as IMS Health)HQ: London, UK

    IQVIA's UK operations provide prescription data analytics, real-world evidence, and secondary pharmaceutical intelligence drawn from NHS and primary care datasets. Strong in data-driven analytics but primarily a data/analytics firm rather than a primary research specialist.

    Best for

    • UK prescription analytics and market data
    • Real-world evidence and health outcomes
    • Secondary pharmaceutical intelligence
    3

    Research Partnership

    Est. 1997HQ: London, UK

    Research Partnership is a UK-headquartered global pharmaceutical and healthcare market research agency, part of Inizio Advisory. Known for full-service custom research across brand strategy, launch, and patient journey work, with broad international reach. A strong generalist pharma MR firm with global scale.

    Best for

    • Global pharmaceutical market research
    • Brand strategy and launch research
    • Patient and HCP qualitative and quantitative studies
    4

    Adelphi Research

    Est. 1996HQ: Bollington, Cheshire, UK

    Adelphi Research is a UK-based global healthcare and pharmaceutical insight company, part of the Omnicom group. Known for therapy-area expertise, syndicated disease-specific programmes, and large multi-country HCP and patient research. A well-established insight specialist with strong international capability.

    Best for

    • Global pharmaceutical and healthcare insight
    • Therapy area and disease landscape research
    • Syndicated and custom HCP studies
    5

    Ipsos UK

    Est. 1975 (Ipsos founded)HQ: London, UK

    Ipsos UK is the UK arm of the global Ipsos group, providing healthcare, patient, consumer, and public sector research. Broad panel reach and brand tracking capability with generalist research strengths across NHS, government, and commercial clients.

    Best for

    • HCP quantitative surveys and panels
    • Patient and consumer health research
    • Brand tracking and public health research
    6

    Lumanity

    Est. 2022 (formed via merger)HQ: UK (multiple sites) · Global

    Lumanity is a market access, HEOR, and insight consultancy with significant UK presence, formed from the merger of established consultancies. Strong in NICE-aligned value evidence, HTA submission support, and health economics rather than broad primary market research, making it a specialist market access partner.

    Best for

    • Market access and value strategy
    • Health economics and outcomes research (HEOR)
    • Insight and evidence for HTA submissions
    7

    Mtech Access

    Est. 2009HQ: Bicester, Oxfordshire, UK

    Mtech Access is a UK market access and HEOR consultancy known for NHS insight, payer engagement, and health technology assessment support. Strong in NICE and NHS-facing market access work and real-world NHS engagement rather than full-service global primary research.

    Best for

    • UK market access consultancy
    • NHS insight and engagement
    • Health economics and HTA support

    KOL Mapping and Payer Research in the UK

    UK KOL mapping requires tracking influence across major academic medical centres and NHS trusts. London centres (UCLH, Guy's and St Thomas', The Royal Marsden, Imperial) hold strong guideline and publication influence in oncology, cardiovascular, and immunology; Cambridge and Oxford (Addenbrooke's, Oxford University Hospitals) combine academic prominence with large trial enrolment; Manchester, Edinburgh, and Cardiff anchor influence across the North of England and the devolved nations. Effective UK KOL mapping segments influence by nation, institution, therapy area, and clinical leadership role.

    UK payer research requires access to national HTA stakeholders and ICB medicines optimisation and formulary decision-makers — the most commercially important respondents in UK pharmaceutical research. Payer interviews cover NICE evidence thresholds, SMC and AWMSG requirements, formulary and commissioning preferences, cost-effectiveness benchmarks, and VPAG affordability dynamics. BioNixus conducts national HTA and local ICB payer interviews as dedicated payer research programmes.

    BioNixus conducts KOL mapping and payer research across the UK in oncology, cardiovascular, immunology, rare disease, metabolic, and other specialty areas. See our UK pharmaceutical market research guide and top healthcare market research companies in the UK for details.

    Methodology & Selection Criteria

    This guide profiles firms with demonstrated market research operations in the UK as of 2026. Selection criteria: (1) active UK operations with verified research capability, (2) relevance to healthcare, pharmaceutical, or consumer buyers in the UK, (3) established track record in UK market research. Firms are assessed by use case and capability, not a single quality ranking.

    BioNixus wrote this guide and is included in it. For corrections or updates, contact our team.

    Frequently Asked Questions

    Who are the top market research companies in the UK in 2026?

    Leading market research companies in the UK in 2026 include BioNixus, IQVIA UK, Research Partnership, Adelphi Research, Ipsos UK, Lumanity, and Mtech Access. BioNixus is a market research company that runs MHRA- and NICE-aligned primary research in the United Kingdom, with verified HCP recruitment at leading NHS trusts and academic medical centres, and deep payer intelligence across NICE technology appraisals, the SMC in Scotland, and the AWMSG in Wales.

    What is pharmaceutical market research in the UK?

    Pharmaceutical market research in the UK encompasses primary and secondary research designed to support commercial, market access, and regulatory decisions within the NHS-centred healthcare system. This includes HCP attitude-and-usage surveys, KOL mapping at academic medical centres and NHS trusts, payer research aligned to NICE technology appraisals, SMC and AWMSG submissions, and health economics research. The UK's single-payer NHS makes payer research structurally different from the US multi-PBM environment — funding and access decisions are concentrated in NICE and national HTA bodies and operationalised through Integrated Care Boards (ICBs) rather than distributed across commercial payers.

    How do NICE and the NHS affect pharmaceutical market research in the UK?

    NICE (the National Institute for Health and Care Excellence) conducts technology appraisals that determine whether medicines are recommended for NHS funding in England. The Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) perform equivalent roles in Scotland and Wales. For market researchers, these bodies create specific research requirements: cost-effectiveness and budget impact evidence aligned to NICE reference-case methodology, willingness-to-pay benchmarking relative to NICE QALY thresholds, payer perception research among NICE committee and ICB stakeholders, and price sensitivity studies that account for VPAG pricing constraints and confidential commercial arrangements.

    What payer research does BioNixus conduct in the UK?

    BioNixus conducts UK payer research spanning national HTA bodies and local commissioners, including in-depth interviews informed by NICE technology appraisal and HST processes, SMC and AWMSG submission requirements, and Integrated Care Board (ICB) medicines optimisation and formulary decision-makers. BioNixus also covers NHS trust pharmacy and finance stakeholders and conducts NICE evidence-alignment research for products approaching HTA submission. Payer research is designed around the specific decision criteria applied at each national HTA body and at local ICB level.

    How much does market research cost in the UK?

    BioNixus custom research projects typically cost $10,000–$60,000, depending on audience, sample, method and number of countries. You get a scoped proposal after a short call.

    Is BioNixus GDPR- and ABPI-compliant for HCP research in the UK?

    Yes. BioNixus designs and executes UK HCP research in accordance with UK GDPR and the Data Protection Act 2018, and aligned to the ABPI Code of Practice governing interactions with healthcare professionals. Studies involving HCPs at NHS trusts and academic medical centres are designed with appropriate consent procedures, fair-market-value honoraria, adverse-event reporting processes, and data privacy protections appropriate to research involving NHS staff and patient-adjacent data.

    What is VPAG and how does it affect UK pharmaceutical strategy?

    VPAG (the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth) is the UK agreement between the government, NHS, and industry that governs branded medicine spend, including rebate (clawback) rates on company sales above an agreed allowed growth rate. VPAG replaced the previous VPAS scheme. For pharmaceutical market researchers, VPAG creates specific research requirements: understanding the net price impact of clawback rates on portfolio strategy, willingness-to-pay studies relative to NICE thresholds under VPAG constraints, and tracking of payer and ICB attitudes toward value and affordability in a capped-spend environment.

    Can UK market research connect to global benchmarking?

    Yes. BioNixus connects UK research to global benchmarking programmes using consistent instruments and methodology across markets. UK HCP and payer studies can be benchmarked against US, EU5, Canada, and other international cohorts — essential for global pharmaceutical clients making simultaneous market access decisions across multiple countries. The UK is frequently included in global launch sequencing alongside the US and EU5, making consistent cross-market research design a practical necessity for global pharma clients.

    Related Resources

    Pharmaceutical companies in the UK

    The companies we study — manufacturers, MNCs, and distributors.

    Top Healthcare Market Research Companies UK 2026

    Deep dive into the top healthcare and pharma research firms in the UK — NICE alignment, KOL mapping, and NHS payer research.

    Pharmaceutical Market Research UK

    MHRA- and NICE-aligned pharmaceutical research covering HCP surveys, KOL mapping, NHS payer research, and VPAG intelligence.

    Healthcare Market Research UK

    UK healthcare research overview — HCP surveys, payer research, HEOR, and patient studies across the NHS.

    UK Healthcare Market Report

    Market sizing, MHRA and NICE landscape, VPAG outlook, and NHS and ICB payer environment.

    Top Market Research Companies USA 2026

    General market research firms operating across the USA for 2026.

    Top Healthcare Market Research Companies USA 2026

    IRB-compliant, PBM-aware healthcare research firms across the USA.

    48-hour proposal

    Need brand and competitor data in the UK?

    Account-level or SKU-level primary research — not a syndicated dashboard. Proposal ready within 48 hours of a brief.

    Planning research in United Kingdom?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.
    View UK Research Capabilities